Evidence memo / Metabolic & weight

Amycretin

Also: GLP-1/amylin receptor agonist

Amycretin is an investigational single molecule that activates both the GLP-1 and amylin receptors, being developed for obesity in injectable and oral forms. It is not approved. Early trials have reported weight effects. The Watchlist boundary is keeping it to its investigational obesity program and separating the oral and injectable versions.

Controlled human dataPhase 2 / Phase 3InvestigationalSafety / regulatory watch

The verdict

Our read at a glance.

Whether amycretin's combined GLP-1 and amylin activity delivers durable weight loss in larger trials and leads to approval.

The signal
Early trials have reported weight loss in obesity for amycretin, with both oral and injectable forms studied. As an early-stage investigational drug, its full efficacy and safety are not yet established and the evidence base is still limited.
The unknown
Whether the early weight signal holds up in larger trials, how tolerability behaves, and how it compares with approved and other investigational incretin drugs.
Our read
An early but closely watched investigational obesity drug, not yet proven or approved. Amycretin's GLP-1 and amylin approach is novel, but the evidence is still early, so it should be read as investigational.

The mechanism

How it works.

Amycretin is a single molecule engineered to activate both the GLP-1 receptor and the amylin receptor. GLP-1 signals the brain and gut to reduce appetite, and amylin (a hormone the pancreas releases alongside insulin) slows stomach emptying and reinforces the feeling of fullness, so hitting both should suppress eating more than either alone. It is being developed as both an injection and a tablet, which are formulated differently, and because it is early-stage these effects are still being established in trials.

Safety & regulatory boundary

The consequential part.

Amycretin is investigational and at an early stage, not an approved product. Its safety profile, including gastrointestinal effects common to incretin and amylin drugs, is still being characterized. The oral and injectable versions are distinct, and research-labeled or compounded amycretin is not an approved product. Its development status does not support use outside trials.

What's next

What we're watching.

Larger Phase 2 and Phase 3 results for the oral and injectable forms, regulatory progress, and comparisons with other incretin drugs.

Context

Why this is discussed.

Amycretin draws attention because it pairs GLP-1 and amylin signaling in a single molecule, with both oral and injectable versions in development.

The evidence base

13 cited references.

Registered trials1

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

ClinicalTrials.gov · PHASE1 · COMPLETED · 2023-09-14

Indexed literature (PubMed)12

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

Dahl K et al. · Lancet · 2025

Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review

Patel JP et al. · Cureus · 2025

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity

Son JW et al. · Endocr Rev · 2026

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities

Bailey CJ et al. · Peptides · 2025

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial

Gasiorek A et al. · Lancet · 2025

Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare

Bhat S et al. · World J Cardiol · 2025

Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives

Fu L et al. · Metabolism · 2026

Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies

Rejili M et al. · Vascul Pharmacol · 2026

Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment

Rudzki G et al. · Pharmaceuticals (Basel) · 2024

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes

Bailey CJ et al. · Peptides · 2026

Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis

Kamrul-Hasan ABM et al. · Endocrinol Diabetes Metab · 2026

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies

Lempesis IG et al. · Metabol Open · 2026

Keep reading

Related published memos.

Thymosin alpha-1RetatrutideTrevogrumabSemaglutide